StockData
Surrozen, Inc./DE logo

Surrozen, Inc./DE (SRZN) stock

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$29.98−2.34 (-7.24%)

Close on Nov 17, 2026Market cap $352.37MP/E –Yield –

Surrozen total assets

Total assets on the balance sheet at the end of each period.

Surrozen's total assets was $115.61M at Jun 30, 2026. For fiscal 2025 it was $98.73M, up 103.7% from the year before. The highest annual figure on record is $137.17M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$98.73M+103.7%
FY2024Dec 31, 2024$48.47M+5.2%
FY2023Dec 31, 2023$46.08M-48.5%
FY2022Dec 31, 2022$89.44M-34.8%
FY2021Dec 31, 2021$137.17M+121.0%
FY2020Dec 31, 2020$62.06M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$115.61M+12.6%
Q1 FY2026Mar 31, 2026$120.71M+5.1%
Q4 FY2025Dec 31, 2025$98.73M+103.7%
Q3 FY2025Sep 30, 2025$94.05M+95.9%
Q2 FY2025Jun 30, 2025$102.70M+127.9%
Q1 FY2025Mar 31, 2025$114.83M+149.2%
Q4 FY2024Dec 31, 2024$48.47M-10.2%
Q3 FY2024Sep 30, 2024$48.00M-25.0%
Q2 FY2024Jun 30, 2024$45.07M-39.3%
Q4 FY2023Dec 31, 2023$46.08M-48.5%
Q3 FY2023Sep 30, 2023$53.97M-41.0%
Q2 FY2023Jun 30, 2023$64.00M-38.5%
Q1 FY2023Mar 31, 2023$74.20M-36.9%
Q4 FY2022Dec 31, 2022$89.44M-34.8%
Q3 FY2022Sep 30, 2022$91.43M-39.3%
Q2 FY2022Jun 30, 2022$104.13M+12.0%
Q1 FY2022Mar 31, 2022$117.66M+25.9%
Q4 FY2021Dec 31, 2021$137.17M+121.0%
Q3 FY2021Sep 30, 2021$150.64M+297076.9%
Q2 FY2021Jun 30, 2021$92.95M–
Q1 FY2021Mar 31, 2021$93.44M–
Q4 FY2020Dec 31, 2020$62.06M–
Q3 FY2020Sep 30, 2020$50.69K–

More Surrozen figures

See a number that looks wrong?